A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Clinical trial NCT03460977 · RECRUITING

Trial details

NCT number: NCT03460977
Sponsor: Pfizer
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Castration Resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer (SCLC)Follicular Lymphoma (FL)

Start date: 2018-04-17
Primary completion: 2028-04-20
Enrollment: 453

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.